Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

June 17, 2024

Takeda, Ascentage Pharma sign option agreement for olverembatinib

Takeda has entered into an option agreement with Ascentage Pharma, securing the opportunity to obtain exclusive global licensing rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI).

Takeda, Ascentage Pharma sign option agreement for olverembatinib